ESPR
Esperion Therapeutics Inc.
$3.12
-$0.01(-0.32%)
47
Overall
40
Value
50
Tech
52
Quality
Market Cap
$640.69M
Volume
6.79M
52W Range
$0.79 - $4.18
Target Price
$2.91
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | $148.4M | $227.5M | $78.4M | $75.5M | $116.3M | $332.3M | $403.1M | ||
| Total Revenue | -- | -- | -- | $148.4M | $227.5M | $78.4M | $75.5M | $116.3M | $332.3M | $403.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | $2.4M | $14.2M | $27.0M | $43.3M | $68.6M | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | -- | $148.4M | $225.2M | $64.2M | $48.5M | $116.3M | $332.3M | $403.1M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-76.2M | $-169.0M | $-204.6M | $241.5M | $348.9M | $305.2M | $228.0M | $271.9M | $277.9M | $342.9M | ||
| Research & Development | $57.9M | $147.6M | $171.5M | $175.6M | $146.9M | $106.0M | $118.9M | $86.1M | $46.2M | $47.9M | ||
| Research Expense | $57.9M | $147.6M | $171.5M | $175.6M | $146.9M | $106.0M | $118.9M | $86.1M | $46.2M | $47.9M | ||
| Selling, General & Administrative | $18.3M | $21.4M | $33.1M | $65.9M | $199.6M | $185.0M | $109.1M | $142.5M | $163.1M | $165.8M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | $19.3M | $13.7M | $11.3M | $15.6M | $25.5M | -- | ||
| General & Administrative Expenses | $18.3M | $21.4M | $33.1M | $65.9M | $199.6M | $185.0M | $109.1M | $142.5M | $163.1M | $165.8M | ||
| Promotion & Advertising | -- | -- | -- | -- | $19.3M | $13.7M | $11.3M | -- | -- | -- | ||
| Salaries & Wages | $-15.6M | $-18.2M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-252.0K | $-258.0K | $-265.0K | $319.0K | $547.0K | $612.0K | $500.0K | $164.0K | $63.0K | -- | ||
| Depreciation & Amortization | $-252.0K | $-258.0K | $-265.0K | $319.0K | $547.0K | $612.0K | $500.0K | -- | -- | -- | ||
| Amortization | $1.0M | $334.0K | $-217.0K | $-200.0K | $-97.0K | $12.0K | $279.0K | $-412.0K | -- | -- | ||
| Other Operating Expenses | $-76.2M | $-169.0M | $-204.6M | $241.5M | $2.4M | $14.2M | $27.0M | $43.3M | $68.6M | $129.2M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-76.2M | $-169.0M | $-204.6M | $-93.1M | $-121.4M | $-226.7M | $-179.5M | $-155.6M | $54.4M | $60.3M | ||
| EBITDA | $-73.3M | $-166.2M | $-201.7M | $-88.9M | $-120.3M | $-222.1M | $-174.7M | $-148.4M | $9.1M | $66.9M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $376.0K | $198.0K | $28.0K | $8.1M | $22.7M | $46.4M | $56.8M | $59.0M | $59.3M | $84.6M | ||
| Net Non-Operating Interest Income/Expense | $-376.0K | $-198.0K | $-28.0K | $-8.1M | $-22.7M | $-46.4M | $-56.8M | $-59.0M | $-59.3M | $-84.6M | ||
| Other Income/Expense | $-1.5M | $-2.0M | $-2.8M | $-4.1M | $-515.0K | $-4.0M | $2.7M | $-5.3M | $46.9M | $-3.5M | ||
| Other Special Charges | $1.5M | $2.0M | $2.8M | $4.1M | $515.0K | $4.0M | $2.7M | $5.3M | $-46.9M | $3.5M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-74.6M | $-166.8M | $-201.8M | $-89.0M | $-120.9M | $-222.8M | $-176.8M | $-150.3M | $7.5M | $63.8M | ||
| Pre-Tax Income | $-75.0M | $-167.0M | $-201.8M | $-97.2M | $-143.6M | $-269.1M | $-233.7M | $-209.2M | $-51.7M | $-20.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.8M | ||
| NET INCOME | ||||||||||||
| Net Income | $-75.0M | $-167.0M | $-201.8M | $-97.2M | $-143.6M | $-269.1M | $-233.7M | $-209.2M | $-51.7M | $-22.7M | ||
| Net Income (Continuing Operations) | $-75.0M | $-167.0M | $-201.8M | $-97.2M | $-143.6M | $-269.1M | $-233.7M | $-209.2M | $-51.7M | $-22.7M | ||
| Net Income (Discontinued Operations) | $-75.0M | $-167.0M | $-201.8M | $-97.2M | $-143.6M | $-269.1M | $-233.7M | $-209.2M | $-51.7M | $-22.7M | ||
| Net Income (Common Stockholders) | $-75.0M | $-167.0M | $-201.8M | $-97.2M | $-143.6M | $-269.1M | $-233.7M | $-209.2M | $-51.7M | $-22.7M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-212.6M | -- | -- | -- | $-20.6M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-76.2M | $-169.0M | $-204.6M | $241.5M | $348.9M | $305.2M | $255.0M | $271.9M | $277.9M | $342.9M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $22.5M | $23.9M | $26.8M | $27.1M | $27.5M | $28.9M | $66.4M | $103.1M | $187.2M | $207.9M | ||
| Average Shares Outstanding (Diluted) | $22.5M | $23.9M | $26.8M | $27.1M | $27.5M | $28.9M | $66.4M | $103.1M | $187.2M | $207.9M | ||
| Shares Outstanding | $22.6M | $26.5M | $26.8M | $27.5M | $27.9M | $62.8M | $76.6M | $185.1M | $197.8M | $256.8M | ||
| Basic EPS | -- | -- | -- | $-3.59 | $-5.23 | $-9.31 | $-3.52 | $-2.03 | $-0.28 | $-0.11 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-3.59 | $-5.23 | $-9.31 | $-3.52 | $-2.03 | $-0.28 | $-0.11 | ||
| Diluted EPS | $-3.33 | $-6.98 | $-7.54 | $-3.59 | $-5.23 | $-9.31 | $-3.52 | $-2.03 | $-0.28 | $-0.11 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-9.31 | $-3.52 | $-2.03 | $-0.28 | $-0.11 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $18.3M | $21.4M | $33.1M | $65.9M | $199.6M | $185.0M | $109.1M | $142.5M | $163.1M | $165.8M | ||
| Rent And Landing Fees | $18.3M | $21.4M | $33.1M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ESPR | $3.12 | -0.3% | 6.79M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Esperion Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW